29th - 30th October, 2020

4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

ILEC Conference Center and IBIS London Earls Court, 47 Lillie Road, London, SW6 1UD

In the past decade, many scientific breakthroughs have been achieved through research including success in recent years of cancer immunotherapy with monoclonal antibodies, cancer vaccines, adoptive cell therapy and immune-checkpoint therapy. Personalized immunotherapy with various combinations will be the next promising strategy for the future cancer treatment direction.

  • 30+ experts from academia and industry will be presenting their current work in Immuno-Oncology, Latest updates on regulatory guidelines and approvals, Validation markers for tumor-derived T-cell subpopulations, NextGen T-Cell and CAR-T Cell therapy, Personalized Medicine, Biomarkers and Cancer Immunotherapy
  • Opportunity to develop long-lasting business relationships and networking opportunities with researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies, Universities, and Research institutes.
  • Over 20 presentations, round-tables, and panel discussions focused on the key opportunities and challenges in biomarker research, Validation methods and innovative tools in IO Discovery, Oral T-Cell Therapies for the Treatment of Cancer Patients and Discovery of novel bispecific antibody molecules to boost anti-tumor immunity

Our 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress to be held on 12th-13th March 2020 in London, UK would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors. This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.

CONFERENCE SPEAKERS

Advisors
Stefan Gluck
Stefan Gluck
Vice President
Celgene, USA
Eugene Zhukovsky
Eugene Zhukovsky
Chief Scientific Officer
Biomunex Pharmaceuticals, France
Sophia Karagiannis
Sophia Karagiannis
Professor, Translational Cancer Immunology and Immunotherapy
King’s College London, UK
Speakers
Roy Baynes
Roy Baynes
Senior Vice President and Head, Global Clinical Development, Chief Medical Officer
Merck Research Laboratories
Shailendra Singh (Shelly)
Shailendra Singh (Shelly)
Chief Operating Officer
MarketsandMarkets
Steven F. Schellings
Steven F. Schellings
Associate Director, Cellular Therapy, Account Management
Novartis, USA
Stefan Gluck
Stefan Gluck
Vice President
Celgene, USA
Bruno Tullia
Bruno Tullia
Assistant Professor
UPMC Hillman Cancer Center, USA
Lindy Durrant
Lindy Durrant
Professor, Cancer Immunotherapy
University of Nottingham, UK
Junjian Liu
Junjian Liu
Vice President, Biologics Discovery
Innovent Biologics, China
Sebastien Tabruyn
Sebastien Tabruyn
CSO
TransCure bioServices SAS, France
Eugene Zhukovsky
Eugene Zhukovsky
Chief Scientific Officer
Biomunex Pharmaceuticals, France
Andrew Sewell
Andrew Sewell
Professor, Division of Infection and Immunity
Cardiff University, UK
Ann White
Ann White
Senior Principal Scientist
UCB Celltech, UK
Sophia Karagiannis
Sophia Karagiannis
Professor, Translational Cancer Immunology and Immunotherapy
King’s College London, UK
Scott Durum
Scott Durum
Head, Cytokines and Immunity
NIH
Ali Roghanian
Ali Roghanian
Assistant Professor, Cancer Immunology
University of Southampton, UK
Jenny Schroeder
Jenny Schroeder
Group Leader, Global R&D Discovery Solutions
Lonza, Germany
Soldano Ferrone
Soldano Ferrone
Professor of Surgery
Harvard University, USA
Sheeba Irshad
Sheeba Irshad
CRUK Clinician Scientist & Honorary Medical Oncologist
Guy’s Hospital, UK
David Gilham
David Gilham
Vice President, R&D
Celyad, UK
John Maher
John Maher
Chief Scientific Officer
Leucid Bio, UK
Angela Vasaturo
Angela Vasaturo
Senior Field Application Scientist
Ultivue, UK
Aude De Gassart
Aude De Gassart
Director of Preclinical Research
ImCheck Therapeutics, France
Asher Nathan
Asher Nathan
CEO
NeoTX Therapeutics, Israel
Will Arends
Will Arends
Chartered (UK) and European Patent Attorney
Marks & Clerk, UK
Vivian Barak
Vivian Barak
Head, Immunology Lab for Tumor Diagnosis
Hadassah Medical Center, Israel
Stephen Harper
Stephen Harper
Group Leader, Protein Science
Immunocore, UK
Markus Zettl
Markus Zettl
Director, Immuno-Oncology
Pieris Pharmaceuticals, Germany
Ian Pike
Ian Pike
Chief Scientific Officer
Proteome Sciences
Pirouz Daftarian
Pirouz Daftarian
Senior Manager, Applications for Immunooncology and Vaccines
JSR Micro Life Sciences and MBL International
Fabienne Hermitte
Fabienne Hermitte
Vice President, Medical Affairs
HalioDx
Saskia Roesch
Saskia Roesch
Global Product Manager, T-Cell Immunology
Miltenyi Biotech
Renier Heijkants
Renier Heijkants
Senior Scientist
APO-T
Nathalie Conte
Nathalie Conte
PDX Finder Project Lead
The European Bioinformatics Institute
Marsilio Adriani
Marsilio Adriani
Principal Scientist
4D Pharma
Christie Zhang
Christie Zhang
Project Team Leader
Elstar Therapeutics
Graham Pawelec
Graham Pawelec
Professor
University of Tuebingen
Justyna Rzepecka
Justyna Rzepecka
Principal Scientist Immunology
Concept Lifesciences
Colin Self
Colin Self
CEO
Precision Therapeutics
David Sansom
David Sansom
Professor
University College London
Manish	Kumar
Manish Kumar
Product Manager Cells and Media
PromoCell
Danny Wells
Danny Wells
Principal Investigator
Parker Institute for Cancer Immunotherapy, USA
Debiprasad Roy
Debiprasad Roy
Senior Director, R&D Technology Platforms
Allogene Therapeutics, USA

SPONSORS

LOCATION

ILEC Conference Center and IBIS London Earls Court, 47 Lillie Road, London, SW6 1UD
About the Hotel

A west London gem, The venue is known to the expert planner for the formidable flexibility and large capacity. The sleek design of the main hall, the London Suite, is positively favored for its ingenious partitioning and dazzling night-ambiance. Thus whether you are looking for an exhibition space, a meeting, an award ceremony, a corporate summer or Christmas party or a conference venue in London, our award-winning team will be certain to deliver the event you need and want.